Dashboard
1
With a growth in Net Sales of 22.2%, the company declared Very Positive results in Sep 25
- The company has declared positive results in Jan 70 after 6 consecutive negative quarters
- PRE-TAX PROFIT(Q) At CNY 198.12 MM has Grown at 494.74%
- NET PROFIT(Q) At CNY 158.28 MM has Grown at 706.84%
- RAW MATERIAL COST(Y) Fallen by -11.85% (YoY)
2
With ROE of 4.51%, it has a fair valuation with a 1.74 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,671 Million (Large Cap)
39.00
NA
4.48%
-0.40
6.14%
1.21
Revenue and Profits:
Net Sales:
1,350 Million
(Quarterly Results - Dec 2025)
Net Profit:
-128 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.83%
0%
-7.83%
6 Months
-3.99%
0%
-3.99%
1 Year
-5.95%
0%
-5.95%
2 Years
-35.53%
0%
-35.53%
3 Years
-48.15%
0%
-48.15%
4 Years
-48.37%
0%
-48.37%
5 Years
-61.17%
0%
-61.17%
By-health Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.52%
EBIT Growth (5y)
66.71%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.63
Tax Ratio
29.36%
Dividend Payout Ratio
92.88%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
21.48%
ROE (avg)
14.00%
Valuation key factors
Factor
Value
P/E Ratio
39
Industry P/E
Price to Book Value
1.74
EV to EBIT
22.91
EV to EBITDA
15.97
EV to Capital Employed
2.30
EV to Sales
2.57
PEG Ratio
NA
Dividend Yield
3.14%
ROCE (Latest)
10.06%
ROE (Latest)
4.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
1,350.10
1,104.80
22.20%
Operating Profit (PBDIT) excl Other Income
-118.10
-98.00
-20.51%
Interest
3.20
1.30
146.15%
Exceptional Items
16.80
-9.60
275.00%
Consolidate Net Profit
-127.70
-214.30
40.41%
Operating Profit Margin (Excl OI)
-139.90%
-147.10%
0.72%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 22.20% vs -31.10% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 40.41% vs -42.11% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,218.40
6,805.50
-8.63%
Operating Profit (PBDIT) excl Other Income
1,178.80
998.80
18.02%
Interest
15.80
13.80
14.49%
Exceptional Items
27.70
28.00
-1.07%
Consolidate Net Profit
816.60
647.90
26.04%
Operating Profit Margin (Excl OI)
142.90%
109.20%
3.37%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -8.63% vs -26.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 26.04% vs -63.58% in Dec 2024
About By-health Co., Ltd. 
By-health Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






